PARIS (PRWEB) March 24, 2008
ART recently leased a manufacturing facility (20,000 square feet) as a result of mastering proprietary polymer-based manufacturing technology to produce bioresorbable stents. The company's bioresorbable stents, which can be manufactured at very low cost, are designed to dismantle in vivo over an optimized time horizon, thus allowing the body's natural arterial remodeling process to occur, which is normally restricted by the deployment of permanent metallic stents.
"Given our approach of achieving temporary stenting of a traumatized angioplasty site, we fully expect to benefit greatly from Machiel Van Der Leest's understanding of the development, regulatory, clinical, manufacturing and market dynamics of the stent sector," said Patrick Sabaria, founder, investor, and CEO of ART as well as former Vice President, Europe, for J&J Interventional Systems, where he introduced the world's first approved-for-marketing coronary stent, the Palmaz stent.
Prior to Minvasys, Van Der Leest was Director of R&D for Cathnet-Science (Nycomed Amersham Medical Systems, or "NAMS", until July 2000) from Sept. 1999 through May 2003. He joined NAMS in March 1999 as Project Engineer, directing the relocation of the company's manufacturing operations from France to Denmark. He is trilingual (English, French, Dutch) and received a master's degree in Industrial Design Engineering from the Technical Univ. Delft, Netherlands, in 1996.
About Arterial Remodeling Technologies ("ART")
Arterial Remodeling Technologies ("ART") is developing bioresorbable peripheral and coronary polymer stents that promote the natural remodeling of an injured artery after angioplasty. The Company's technology is based on intellectual property originating from three esteemed institutions: the Cleveland Clinic; the French national research institute, C.N.R.S. (Centre National de Recherche Scientifique), Montpellier, France; and, Necker University, Paris. To date, ART has raised EUR 10 ($14.2) million in venture capital from investors Matignon Technologies and SGAM Alternative Investments.